Related Experiment Video
Updated: Feb 21, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
USE OF WARFARIN IN PEDIATRICS: CLINICAL AND PHARMACOLOGICAL CHARACTERISTICS
Bruna Bergmann Santos1, Isabela Heineck1, Giovanna Webster Negretto2
1Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil.
Insights
Warfarin anticoagulation in children is complex, with central venous catheters being a major risk factor for thrombotic events. Infants and those on total parenteral nutrition require higher doses and longer monitoring for effective warfarin therapy.
Area of Science:
- Pediatric Pharmacology
- Hematology
- Clinical Pharmacy
Background:
- Oral anticoagulation with warfarin is crucial for preventing thrombotic events in children.
- Understanding factors influencing warfarin efficacy and safety in pediatric populations is essential for optimizing treatment.
Purpose of the Study:
- To analyze pediatric responses to warfarin, focusing on age, clinical status, administration route, and total parenteral nutrition (TPN).
- To identify risk factors associated with thrombotic events (TE) in children receiving warfarin therapy.
Main Methods:
- A retrospective descriptive study of pediatric patients (≤18 years) treated with warfarin at a university hospital.
- Data collection from medical records, analyzing risk factors for TE, time to therapeutic International Normalized Ratio (INR), and adverse events.
Main Results:
- Central venous catheter use was the primary risk factor for TE (89.6%).
- Patients with short bowel syndrome and TPN required higher warfarin doses for target INR.
- Infants (≤1 year) needed longer periods and higher doses for anticoagulation compared to older children.
Conclusions:
- Pediatric warfarin therapy is complex, necessitating standardized protocols.
- Development of clinical practice guidelines is recommended to manage anticoagulation effectively in children.
Objective:
To describe how children respond to oral anticoagulation with warfarin, verifying the influence of age, clinical condition, route of administration of warfarin and use of total parenteral nutrition (TPN), as well as to describe risk factors for the occurrence of thrombotic events (TE) in childhood.
Methods:
A retrospective descriptive study including all patients ≤18 years old for whom warfarin was prescribed in a university hospital. Patients were divided according to clinical condition, age, route of medication administration and use of TPN. Data was collected from the patients' medical records and the analysis considered the risk factors for TE already described in the literature, the time and the dose required in order to reach the first International Normalized Ratio (INR) in the target and the adverse events in this period. After reaching the INR, the maintenance of anticoagulation was verified by the prescribed dose and INR tests.
Results:
Twenty-nine patients were included in the study. The major risk factor for TE was the use of a central venous catheter in 89.6% of the patients. Patients with short bowel syndrome and total parenteral nutrition required significantly higher doses (p≤0.05) to achieve and maintain the INR in the target. Patients ≤1 year old needed longer periods and required an increased dose of anticoagulation and maintenance than older patients. The mean number of INR examinations below the target was 48.2% in the groups studied.
Conclusions:
The observed complexity of anticoagulant therapy reinforces the need to develop protocols that guide clinical practice.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Dosing: Infants and Children

